HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

tipranavir

inhibits HIV-1 protease; structure in first source

Also Known As:

Aptivus; PNU 140690; PNU-140690; tipranavir, (R-(R*,R*))-isomer; tipranavir, (S-(R*,R*))-isomer; tipranavir, (S-(R*,S*))-isomer

Networked: 40 relevant articles (2 outcomes, 4 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 25
- Pyrans: 3
  - Pyrones: 18
    - tipranavir: 40
- 1-Ring Heterocyclic Compounds
  - Pyridines: 28
    - tipranavir: 40
  - Pyrans: 3
    - Pyrones: 18
      - tipranavir: 40

Experts

1.	Rusconi, Stefano: 2 articles (07/2009 - 03/2004)
2.	Temesgen, Zelalem: 2 articles (09/2007 - 11/2005)
3.	De Clercq, E: 2 articles (01/2007 - 04/2002)
4.	Arribas, Jose R: 1 article (11/2009)
5.	Soriano, Vincent: 1 article (10/2009)
6.	Rodríguez-Novoa, Sonia: 1 article (10/2009)
7.	Morello, Judit: 1 article (10/2009)
8.	Jiménez-Nácher, Inmaculada: 1 article (10/2009)
9.	González-Pardo, Gema: 1 article (10/2009)
10.	González-Lahoz, Juan: 1 article (10/2009)

Related Diseases

1.	HIV Infections (HIV Infection) 02/01/2009 - "[Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection]" 01/01/2008 - "Tipranavir: a review of its use in the management of HIV infection." 09/15/2007 - "Tipranavir: a new option for the treatment of drug-resistant HIV infection." 05/01/2007 - "Tipranavir, a nonpeptidic HIV-1 protease inhibitor, has been recently approved for the treatment of HIV infection. " 11/01/2003 - "Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection." Order ALL the reference details at left...
2.	Acquired Immunodeficiency Syndrome (AIDS) 10/01/2009 - "Three genotypic inhibitory quotients (gIQs) were calculated by using different TPV resistance mutation scores (from the International AIDS Society-USA [IAS-USA], Randomized Evaluation of Strategic Intervention in Multidrug-Resistant Patients with Tipranavir [RESIST], and Agence Nationale de Recherches sur le Sida et les Hépatites Virales [ANRS] trials). " 06/01/2008 - "The tipranavir response by FIV may 1) support the idea of using FIV as a small animal model for PI-resistant HIV-1, thus expanding access to animal AIDS models; and 2) pave the way for development of novel broad-based inhibitors for treatment of drug resistant HIV-1." 07/01/2009 - "Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resistant strains, can be used in salvage therapies for multi-experienced HIV patients due to its peculiar resistance profile including 21 mutations at 16 protease positions according to International AIDS Society (IAS). " 01/01/2008 - "The results suggest that the two inhibitors nelfinavir and tipranavir could be used for treatment of AIDS by targeting the enzyme HIV protease as neither of the two inhibitors exhibit any cross-reactivity with other human proteins, they readily bind to the mutated enzyme active site and still remain linked with the enzyme-substrate complex in the presence of water molecules. " 01/01/2007 - "There are, at present, twenty-two anti-HIV drugs which have been formally licensed for clinical use in the treatment of HIV infections (AIDS): zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine, tenofovir, nevirapine, delavirdine, efavirenz, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir, darunavir and enfuvirtide. " Order ALL the reference details at left...
3.	Meningitis 07/01/2008 - "To the best of our knowledge, this is the first reported case of intracranial haemorrhage related to Tipranavir treatment after the end of the "RESIST" studies and the only one related to meningitis." Order ALL the reference details at left...
4.	Erectile Dysfunction 06/01/2007 - "For other drugs such as antiarrhythmics, antihistamines, ergot derivatives, selective serotonin receptor agonists (or triptans), gastrointestinal motility agents, erectile dysfunction agents, and calcium channel blockers, interactions can be predicted based on studies with other ritonavir-boosted protease inhibitors and what is known about tipranavir-ritonavir CYP and P-glycoprotein utilization. " Order ALL the reference details at left...
5.	Infection 11/01/2008 - "BACKGROUND: Tipranavir-resistance associated mutations (TPV-RAMs) are often observed among patients with HIV-1 subtype A/E infection. " 11/01/2008 - "Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection." 01/01/2008 - "Thus, tipranavir, administered with ritonavir, is an effective treatment option for use in the combination therapy of adults with HIV-1 infection who have been previously treated with other antiretroviral drugs." 01/01/2008 - "In treatment-experienced adults with HIV-1 infection receiving an optimized background regimen, viral suppression was greater and immunological responses were better with regimens containing tipranavir/ritonavir than with comparator ritonavir-boosted PI-containing regimens. " 03/01/2004 - "CONCLUSIONS: Our in vitro experiments did not show any advantage in combining second generation PIs as a therapeutic strategy in naive or multi-treatment failure subjects, with the exception of tipranavir + amprenavir at IC(95) in infections by a wild-type isolate." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Protease Inhibitors (Protease Inhibitor)
2.	Ritonavir (Norvir)
3.	P-Glycoprotein
4.	Serotonin Agonists (Serotonin Receptor Agonists)
5.	Tryptamines (Triptans)
6.	Histamine Antagonists (Antihistamines)
7.	Calcium Channel Blockers (Blockers, Calcium Channel)
8.	darunavir (Prezista)
9.	lopinavir (Kaletra)
10.	atazanavir (Reyataz)

Related Therapies and Procedures

1.	Salvage Therapy
2.	Highly Active Antiretroviral Therapy (HAART)
3.	Stents

blog comments powered by Disqus

TREATMENT OPTIONS
for HIV Infections,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 542 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>